MedTrace Logo

Cardiovascular Biomarkers and Quetiapine in Depression and Anxiety Patients

NCT00951483 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2016-10-24

Study results available
· View outcomes & findings →

Summary

No suitable treatment has been identified to reverse and ideally prevent, the cardiovascular disease risk associated with depression and anxiety. The purpose of this study is to determine if quetiapine treatment of depression can reverse the signs of arterial stiffening that often occurs in depression and anxiety, and which are believed to be risk factors for future heart disease.

Conditions

Interventions

DRUG

Quetiapine-XR

Quetiapine-XR (Seroquel-XR) 50-300mg daily for 12 weeks.

Sponsors & Collaborators

  • Loyola University

    lead OTHER

Principal Investigators

  • Angelos Halaris, MD, PhD · Loyola University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00951483 on ClinicalTrials.gov